<DOC>
	<DOCNO>NCT00197002</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety GSK Biologicals 2-dose inactivate hepatitis A vaccine administer pneumococcal conjugate vaccine child young 15 month age .</brief_summary>
	<brief_title>Immune Response &amp; Safety Hepatitis A Vaccine Given Together With Pneumococcal Vaccine Healthy Children 15 Age</brief_title>
	<detailed_description>An open , control comparison Havrix administer alone Prevnar . The three group evaluate : 1 ) Havrix alone , 2 ) Havrix plus Prevnar 3 ) Prevnar follow Havrix one month later .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female child 12 13 month age time entry Enrollment Phase , Free obvious health problem , Subjects must previously receive three dos Prevnar his/her first year life . Use investigational nonregistered drug vaccine within 42 day precede first dose study vaccine , plan use study period , Chronic administration immunosuppressant immunemodifying drug within six month prior vaccination plan administration time study period . ( For corticosteroid , mean prednisone , equivalent , less 0.5 mg/kg/day . Inhaled , nasal topical steroid allow . ) , Administration ACIPrecommended fourth dose Prevnar prior enter Enrollment Phase study , Planned administration administration vaccine foreseen study protocol within period 42 day 30 day dose study vaccine ( ) , Previous vaccination hepatitis A , History hepatitis A known exposure hepatitis A , Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , A family history congenital , hereditary infectious immunodeficiency parental risk factor HIV infection , History allergic disease/reactions hypersensitivity likely exacerbate component Havrix ( e.g. , neomycin , 2phenoxyethanol ) Prevnar ( e.g. , diphtheria toxoid ) , Major congenital defect serious chronic illness , History neurologic disorder ( history febrile seizure associate underlying neurological disorder exclude subject ) , Acute disease , define presence moderate severe illness without fever , time vaccination , Administration immunoglobulins and/or blood product within three month prior first dose study vaccine plan administration time entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>13 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>